Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–3058.
   PubMed Web of Science ®Google Scholar
• Dosani T, Carlsten M, Maric I, et al. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma and their uses in immunotherapies. Blood Cancer J. 2015;5:e306.
   PubMed Web of Science ®Google Scholar
• Görgün G, Samur MK, Cowens KB, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res. 2015;21:4607–4618.
   PubMed Web of Science ®Google Scholar
• Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015;29:2110–2113.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Tamura H, Satoh C, et al. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clin Cancer Res. 2009;15:770–777.
   PubMed Web of Science ®Google Scholar
• Nair JR, Carlson LM, Koorella C, et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol. 2011;187:1243–1253.
   PubMed Web of Science ®Google Scholar
• Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012;7:e35981.
   PubMed Web of Science ®Google Scholar
• Braga WMT, Atanackovic D, Colleoni GWB. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol. 2012;2012:293479.
   PubMed Web of Science ®Google Scholar
• André T, Najar M, Stamatopoulos B, et al. Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells. Cancer Immunol Immunother. 2015;64:213–224.
   PubMed Web of Science ®Google Scholar
• Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res. 2011;317:620–631.
   PubMed Web of Science ®Google Scholar
• Van Raemdonck K, Van den Steen PE, Liekens S, et al. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev. 2015;26:311–327.
   PubMed Web of Science ®Google Scholar
• Rabin RL, Alston MA, Sircus JC, et al. CXCR3 is induced early on the pathway of CD4+ T cell differentiation and bridges central and peripheral functions. J Immunol. 2003;171:2812–2824.
   PubMed Web of Science ®Google Scholar
• Whiting D, Hsieh G, Yun JJ, et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol. 2004;172:7417–7424.
   PubMed Web of Science ®Google Scholar
• Groom JR, Richmond J, Murooka TT, et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity. 2012;37:1091–1103.
   PubMed Web of Science ®Google Scholar
• Winter D, Moser J, Kriehuber E, et al. Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol. 2007;179:4272–4282.
   PubMed Web of Science ®Google Scholar
• Berghuis D, Santos SJ, Baelde HJ, et al. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol. 2011;223:347–357.
   PubMed Web of Science ®Google Scholar
• Hong M, Puaux AL, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71:6997–7009.
   PubMed Web of Science ®Google Scholar
• Chang K-P, Wu C-C, Fang K-H, et al. Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:802–807.
   PubMed Web of Science ®Google Scholar
• Hsin LJ, Kao HK, Chen IH, et al. Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma. PLoS One. 2013;8:e80052.
   Google Scholar
• Mir MA, Maurer MJ, Ziesmer SC, et al. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 2015;125:992–998.
   PubMed Web of Science ®Google Scholar
• Möller C, Strömberg T, Juremalm M, et al. Expression and function of chemokine receptors in human multiple myeloma. Leukemia. 2003;17:203–210.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Bonomini S, Romagnani P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica. 2006;91:1489–1497.
   PubMed Web of Science ®Google Scholar
• Pellegrino A, Antonaci F, Russo F, et al. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 2004;207:221–227.
   PubMed Web of Science ®Google Scholar
• Ponzetta A, Benigni G, Antonangeli F, et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 2015;75:4766--4777.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117:4691–4695.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Hajek R, Tóthová E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 2009;113:3435–3442.
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161:695–700.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol. 2012;2012:196063.
   PubMedGoogle Scholar
• Antonelli A, Ferrari SM, Frascerra S, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2011;96:1859–1863.
   PubMed Web of Science ®Google Scholar
• Croudace JE, Inman CF, Abbotts BE, et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012;120:4246–4255.
   PubMed Web of Science ®Google Scholar
• Duarte GV, Boeira V, Correia T, et al. Osteopontin, CCL5 and CXCL9 are independently associated with psoriasis, regardless of the presence of obesity. Cytokine. 2015;74:287–292.
   PubMed Web of Science ®Google Scholar
• Cao Y, Luetkens T, Kobold S, et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol. 2010;38:860–867.
   PubMed Web of Science ®Google Scholar
• Larsson A, Carlsson L, Gordh T, et al. The effects of age and gender on plasma levels of 63 cytokines. J Immunol Methods. 2015;425:58–61.
   PubMed Web of Science ®Google Scholar
• Barash U, Zohar Y, Wildbaum G, et al. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia. 2014;28:2178–2187.
   PubMed Web of Science ®Google Scholar
• Pérez-Andres M, Almeida J, Martin-Ayuso M, et al. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer. 2006;106:1296–1305.
   PubMed Web of Science ®Google Scholar
• Haabeth OAW, Lorvik KB, Hammarström C, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun. 2011;2:240.
   PubMed Web of Science ®Google Scholar
• Lee N, Shin MS, Kang KS, et al. Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling. Clin Immunol. 2014;152:101–110.
   PubMed Web of Science ®Google Scholar
• Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol. 1999;162:4928–4937.
   PubMed Web of Science ®Google Scholar
• Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104:1041–1050.
   PubMed Web of Science ®Google Scholar
• Reinhart TA, Fallert BA, Pfeifer ME, et al. Increased expression of the inflammatory chemokine CXC chemokine ligand 9/monokine induced by interferon-gamma in lymphoid tissues of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. Blood. 2002;99:3119–3128.
   PubMed Web of Science ®Google Scholar
• Moss P, Gillespie G, Frodsham P, et al. Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia. Blood. 1996;87:3297–3306.
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhães RJ, Vidriales MB, Paiva B, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79–86.
   PubMed Web of Science ®Google Scholar
• Ogawara H, Handa H, Yamazaki T, et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res. 2005;29:135–140.
   PubMed Web of Science ®Google Scholar
• Müller M, Carter SL, Hofer MJ, et al. CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system. J Immunol. 2007;179:2774–2786.
   PubMed Web of Science ®Google Scholar
• Kornete M, Mason ES, Girouard J, et al. Th1-like ICOS + Foxp3+ Treg cells preferentially express CXCR3 and home to β-islets during pre-diabetes in BDC2.5 NOD mice. PLoS One. 2015;10:e0126311.
   Google Scholar
• Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4 + CD25 high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 2006;107:3940–3949.
   PubMed Web of Science ®Google Scholar
• Feyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol. 2009;144:686–695.
   PubMed Web of Science ®Google Scholar